Tenvie Therapeutics

About Tenvie Therapeutics

Tenvie is a company founded to improve the lives of patients and caregivers impacted by neurological, cardiometabolic, and ophthalmic diseases. It is committed to transforming the treatment of these conditions through a tenacious pursuit for life, supported by a proven team of CNS drug developers and a diverse portfolio of small molecule therapies.

Products & Services

Small Molecule Therapeutics:A differentiated and diverse pipeline of small molecule therapeutics engineered to be highly CNS-penetrant or peripherally restricted, targeting inflammation, metabolic dysfunction, and lysosomal function for neurological, cardiometabolic, and ophthalmic diseases.

Specialties

Central Nervous System (CNS) Drug Development Small Molecule Therapeutics Neurological Diseases Cardiometabolic Diseases Ophthalmic Diseases Inflammation Resolution Metabolic Dysfunction Rescue Lysosomal Function Restoration

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Venture Round T: - FT: Venture Round	A: 200000000 MR: - FA: $200 Million FAN: 200000000	D: 2025-01-08 FD: 2025-01-08	3 investors

Venture Round Latest

2025-01-08

$200.0M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Tony Estrada

President & Chief Executive Officer

T

Tanya Fischer

Chief Medical Officer

B

Bill Avery

Senior Vice President, Non-Clinical Safety & Developmental Sciences

C

Chong-Hui Gu

Senior Vice President, CMC & Supply Chain

P

Paul Berns

Executive Chairman | Managing Director, ARCH Venture Partners

K

Kristina Burow

Managing Director, ARCH Venture Partners

View 46 more team members with Pro

Unlock Full Team Directory

Recent News